Clinical Trial Update: A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) [Phase 2]

View source ↗

Summary

Phase 2 pediatric study comparing Axatilimab to Best Available Therapy for chronic graft-versus-host disease after at least two prior systemic therapies is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Axatilimab (axatilimab)

Snippet

Sponsor: Incyte Corporation | Conditions: Chronic Graft-versus-host-disease | Phase 2 | Status: RECRUITING